Clinical Forms of Chikungunya in Gabon, 2010 by Nkoghe, Dieudonné et al.
Clinical Forms of Chikungunya in Gabon, 2010
Dieudonne ´ Nkoghe
1,2*
., Roland Fabrice Kassa
1.,M e ´lanie Caron
1, Gilda Grard
1, Illich Mombo
1, Branly
Bikie ´
1,3, Christophe Paupy
1,4, Pierre Becquart
1,4, Ulrich Bisvigou
1,5, Eric Maurice Leroy
1,4
1Unite ´ des Maladies Virales Emergentes, Centre International de Recherches Me ´dicales de Franceville-CIRMF, Franceville, Gabon, 2Ministe `re de la Sante ´ Publique,
Libreville, Gabon, 3Centre National de la Recherche Scientifique et Technologique, Libreville, Gabon, 4MIVEGEC (IRD 224/CNRS 5290/UM1/UM2), Montpellier, France,
5Faculte ´ de Me ´decine, Universite ´ des Sciences de la Sante ´, Libreville, Gabon
Abstract
Background: Chikungunya virus (CHIKV) has caused multiple outbreaks in tropical and temperate areas worldwide, but the
clinical and biological features of this disease are poorly described, particularly in Africa. We report a prospective study of
clinical and biological features during an outbreak that occurred in Franceville, Gabon in 2010.
Methodology/Principal Findings: We collected, in suspect cases (individuals presenting with at least one of the fol-
lowing symptoms or signs: fever, arthralgias, myalgias, headaches, rash, fatigue, nausea, vomiting, diarrhea, bleeding,
or jaundice), blood samples, demographic and clinical characteristics and outcome. Hematological and biochemical
tests, blood smears for malaria parasites and quantitative PCR for CHIKV then dengue virus were performed. CHIKV+
patients with concomitant malaria and/or dengue were excluded from the study. From May to July 2010, data on 270
laboratory-confirmed CHIK patients were recorded. Fever and arthralgias were reported by respectively 85% and
90% of patients, while myalgias, rash and hemorrhage were noted in 73%, 42% and 2% of patients. The patients were
grouped into 4 clinical categories depending on the existence of fever and/or joint pain. On this basis, mixed forms
accounted for 78.5% of cases, arthralgic forms 12.6%, febrile forms 6.7% and unusual forms (without fever and arthralgias)
2.2%. No cases of organ failure or death were reported. Elevated liver enzyme and creatinine levels, anemia and
lymphocytopenia were the predominant biological abnormalities, and lymphocytopenia was more severe in patients with
high viral loads (p=0.01).
Conclusions/Significance: During CHIK epidemics, some patients may not have classical symptoms. The existence of
unusual forms and the absence of severe forms of CHIK call for surveillance to detect any change in pathogenicity.
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Introduction
Chikungunya fever (CHIK) is a neglected tropical disease
caused by the Chikungunya virus (CHIKV), an arthropod-borne
virus belonging to the genus Alphavirus of the Togaviridae family.
This virus is transmitted to humans via the bite of infected Aedes
mosquitoes (Aedes aegypti, Aedes albopictus). The genome consists of a
single positive strand of RNA that encodes four nonstructural
proteins involved in virus replication and pathogenesis, and five
structural proteins that compose the virion [1]. CHIKV is
subdivided into three genotypes based on phylogenetic analyses.
These genotypes, based on the gene sequences of an envelope
protein (E1), are Asian, East/Central/South African (ECSA), and
West African [2–6].
Over the past two decades, this virus has caused multiple
outbreaks worldwide, particularly in tropical and subtropical
areas. Since its initial isolation in Tanzania in 1953, sporadic cases
and numerous outbreaks have been reported in Africa, India
Ocean Islands, India, and even in Italy, a temperate region.
CHIKV circulated in West and East Africa at low levels until
1999–2000, when an outbreak occurred in the Democratic
Republic of the Congo (DRC) with around 50,000 cases [7].
From 2004, successive epidemics occurred, starting in Kenya with
13,500 cases and then spreading through the Indian Ocean
region, including the Comoros Islands, Mauritius, Mayotte, La
Re ´union Island, Madagascar and the Seychelles [8–13]. On La
Re ´union Island alone, which has a population of 760,000
inhabitants, at least 266,000 cases were reported [14]. Thereafter,
the epidemic arrived on the Indian subcontinent in 2006–2007
and caused more than 1.3 million cases [15]. Genetic analyses
showed that the ECSA genotype was responsible for these
outbreaks [8,16]. Numerous cases were subsequently reported all
over the world [17], directly associated with the return of tourists
from India and affected India Ocean islands [2]. The first reported
European outbreak occurred in two contiguous villages of
northeastern Italy [18].
A unnoticed and retrospectively diagnosed large outbreak hit
Cameroon in 2006 [19], then Gabon one year later, where a
www.plosntds.org 1 February 2012 | Volume 6 | Issue 2 | e1517concomitant CHIKV/dengue virus- serotype 2 (DENV-2) epi-
demic raged in the northwest and north; 20,000 cases were
recorded and Aedes albopictus was identified as the main vector [20].
Isolates from the 2007 Gabon outbreak belonged to the ECSA
phylogroup and harbor the A226V mutation [6].
Thus, the virus has proven able to expand to novel ecological
niches, together with the vector Aedes albopictus [21,22]. Recently,
autochthonous cases of dengue fever (DF) and CHIK were
reported in southern France, where Aedes albopictus has also been
detected, raising serious concerns [23].
CHIK, a word from the Bantu language, means ‘‘that which
contorts or bends up’’ referring to the stooped posture that
develops in infected patients due to severe joint pain and impaired
walking ability.
The clinical manifestations of CHIK are now well described.
The infection is characterized by three distinct forms: asymptom-
atic, classical and severe. The asymptomatic form is revealed
by serology, in naı ¨ve populations. In its classical form, the illness
appears as a ‘‘dengue-like’’ disease, sometimes being confused
with DF, particularly in areas where the two viruses cocirculate
[3,22,24]. After an incubation period of 3–7 days, symptoms
start abruptly with acute fever, followed by severe and often
debilitating polyarthralgias sometimes lasting months or years.
Additional symptoms include a maculopapular rash, myalgias
and headaches [3,22,24]. In La Reunion Island, severe forms
were reported, mainly in patients with underlying medical
conditions. These forms included neurological and cardiovascular
disorders, acute hepatitis, skin diseases, and respiratory and
renal failure. Miscarriages and neonatal infections were also
reported, and some deaths were directly attributed to CHIKV
[3,14,25,26].
In previous studies, clinical and biological descriptions were
mostly retrospective, and included a limited number of pa-
tients. Furthermore, except for the first known CHIKV outbreak
in Tanganyika [27], most studies were conducted in Asia, the
Indian Ocean Islands and Europe [18,25,28,29], while none
have concerned Africa, where multiple pathogens co-circulate
[7,19,20,30–32].
Here, we report the findings of a prospective, exhaustive clinical
and biological study of 270 laboratory-confirmed cases during the
simultaneous CHIKV/DENV outbreak which occurred in
Gabon, a Central African country, in 2010 [33], focusing on the
high clinical variability.
Materials and Methods
Outbreak area
A simultaneous CHIKV/DENV outbreak was reported in two
provinces (Ogooue Lolo and Haut Ogooue) of southeast Gabon,
from April to July 2010. This study took place in Franceville, the
main town of Haut Ogooue province, located 512 km south-east
from Libreville (capital of Gabon) (Figure 1). In Franceville, there
are 4 healthcare capacities, including 2 public hospitals with a total
of 170 beds. The Centre International de Recherches Medicales
de Franceville (CIRMF), which includes a medical unit, is located
in the heart of the city.
Ethical considerations
The CIRMF team partnered the Ministry of Health (MoH)
response team during this outbreak. The investigations (epidemi-
ological and clinical inquiries, blood sampling for laboratory
confirmation) were thus considered as part of the public health
response. According to the MoH’s directives, written consent was
not required due to emergency diagnosis. An oral consent was
obtained for each patient during interviews. The study was
approved by the Regional Health Director, including individual
oral consent for blood sampling (Authorization nu189, Figure S1).
The results were transmitted to patients and MoH.
Study population and clinical examination
The study was conducted in the field by two doctors who
investigated cases in all healthcare facilities of Franceville, while
free medical consultations were provided by another in the
CIRMF medical unit.
At the time of this outbreak, all the hospitals were requested to
sample suspected cases. The case definition adopted by the MoH
included suspected and confirmed cases. Patients were suspected
of having CHIK if they presented with at least one of the following
symptoms or signs: fever (defined as a temperature $38u5,
measured by a HCW), arthralgias, myalgias, headaches, rash,
fatigue, nausea, vomiting, diarrhea, bleeding, or jaundice. A
‘confirmed’ case met the clinical case definition and was PCR-
positive.
Patients with suspected CHIK who were identified by the
CIRMF team were examined physically, then data were collected
on a standardized questionnaire, including age, sex, residence,
time of onset and intensity of symptoms, and location of
arthralgias (Figure S2). Analgesics and non steroidal antiinflam-
matory drugs (paracetamol, ibuprofen) were provided to patients
according to MoH recommendations. If necessary, patients were
hospitalized, and the length of stay was transmitted to our team.
Finally, clinical data on the disease course and outcome were
collected during a 3-month period.
Blood collection and laboratory analyses
Blood samples were collected in two 7-ml EDTA Vacutainer
tubes and one 7-ml dry tube (VWR International, France). The
tubes were stored in the dark at +4uC until arrival at the
laboratory.
Thick and thin blood films were stained with 20% Giemsa and
examined for malaria parasites. Patients with positive test were
excluded from the study. Hematological (Hematology Analyser
ACT 10, Beckman Coulter) and biochemical (creatinine, AST,
ALT) tests were performed (Automatic Analyser Hitachi model
902, Roche Diagnostics).
For molecular studies, RNA was extracted from 140 mLo f
plasma by using the QIAamp Viral RNA Mini Kit according to the
manufacturer’s recommended procedures (Qiagen, Courtaboeuf,
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Chikungunya fever (CHIK) is a disease caused by a virus
transmitted to humans by infected mosquitos. The virus is
responsible for multiple outbreaks in tropical and temper-
ate areas worldwide, and is now a global concern. Clinical
and biological features of the disease are poorly described,
especially in Africa, where the disease is neglected because
it is considered benign. During a recent CHIK outbreak that
occurred in southeast Gabon, we prospectively studied
clinical and biological features of 270 virologically con-
firmed cases. Fever and arthralgias were the predominant
symptoms. Furthermore, variable and distinct clinical
pictures including pure febrile, pure arthralgic and unusual
forms (neither fever nor arthralgias) were detected. No
severe forms or deaths were reported. These findings
suggest that, during CHIK epidemics, some patients may
not have classical symptoms (fever and arthralgias). Local
surveillance is needed to detect any changes in the
pathogenicity of this virus.
Symptoms of Chikungunya in Gabon
www.plosntds.org 2 February 2012 | Volume 6 | Issue 2 | e1517France). cDNA was synthesized in a 9700 thermocycler (Applied
Biosystems, Foster City, CA, USA), where 25 mL of extracted RNA
was mixed with 25 mL of High Capacity cDNA kit (Applied
Biosystems, Foster City, CA, USA). Finally, 5 mL of newly
synthesized cDNA was used as template in 25 mL of TaqMan
Universal PCRMaster Mix and then, thermocycled in a 7500 Real-
Time PCR system (Applied Biosystems).
RNA positive and negative controls were added in each run.
The TaqMan PCR products were identified by curves using a
7500 system SDS software.
The quantitative PCR mix were run with 400 nM of each
primer and 200 nM of probe. The E1 gene (208 bp) was targeted
for the CHIKV detection (genome position, 10387–10595):
CHIK-S (S=Sense): AAGCTYCGCGTCCTTTACCAAG; CHIK-
R (R=Reverse): CCAAATTGTCCYGGTCTTCCT; CHIK-P
(P=Probe): CCAATGTCYTCMGCCTGGACACCTTT [34]. For
DENV detection, the 39 UTR (107 bp) was targeted (genome
position, 10590–10697): DENt-S (t=total, for the 4 serotypes):
AGGACYAGAGGTTAGAGGAGA; DENt-R: CGYTCTGT-
GCCTGGAWTGAT; DENt-P: ACAGCATATTGACGCTGG-
GARAGACC [35]. The probes used for CHIKV, then for DENV
assays were labeled with FAM-reporter and TAMRA-quencher
(Applied Biosystems). Quantified RNA transcripts and cell-culture
supernatants of CHIKV and DENV were used in 10-fold dilutions
as standards for viral load (VL) determination. The VL was
determined by comparison to a standard curve. Thisstandard curve
was obtained from standard RNA which was diluted at 10 in 10
times. Exponential regression was used to determine the CHIKV
viral loads from the threshold cycle. The standard linearity
minimum was ,10
1 cDNA genome equivalents/mL. DENVs were
typed as previously described [35].
Co-infected patients were excluded from this study.
Statistical analyses
Statistical analyses were performed using Epi Info sof-
tware (6.04, Epiconcept). Results were expressed as averages
(with their SD) and percentages (with their 95% confidence
interval, CI). Student’s t test was used to compare laboratory
parameters (samples from 50 healthy volunteers recruited at
the CIRMF medical unit, with sociodemographic characteristics
similar to those of the study subjects, were selected as controls)
and continuous clinical variables. For qualitative variables,
the Chi square test or Fisher’s exact test was used as appro-
priate. A p value ,0.05 was considered to denote statistical
significance.
Results
Outbreak description
From May to July 2010, 2731 suspected cases were recorded in
the two provinces, and 1208 cases (44.2%) were laboratory
confirmed (Table 1). There were 1139 CHIKV+ cases (94.2%) in
Haut Ogooue province. In all, 933/2063 (45.2%) cases were
confirmed in Franceville, representing 81.9% of the confirmed
cases in the province.
The first cases were confirmed on April 25 (week 17), the peak
incidence was reached at weeks 21 and 22 (400 confirmed cases),
and the outbreak ended at week 27 (Figure 2).
Figure 1. Map of Gabon, and location of the different Chikungunya outbreaks from 2007 to 2010.
doi:10.1371/journal.pntd.0001517.g001
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Of the 2063 suspected cases detected in Franceville, 408
(19.8%) were examined by the CIRMF medical team, of whom
289 were CHIKV+, 19 were co-infected (with 18 CHIKV+/
DENV+ patients and 1 CHIKV+/DENV+/malaria+). So, 270
CHIKV+ (66.2%) were selected for the study (Figure 3). The 119
CHIKV- patients did not receive a diagnosis.
They represented 28.9% of all CHIKV+ patients in Franceville.
They were distributed throughout the outbreak, with 99 (36.6%)
patients included at the epidemic peak, in weeks 21 and 22
(Figure 2).
The M/F sex ratio of the study population was 0.85 and mean
age was 30616 years (range, 1–77). Fifty-six patients (20.7%) were
under 16 years old, 70 (26.3%) 16–30 years old, 92 (34.1%) 31–45
years old, and 53 (18.9%) over 45 years old.
Clinical symptoms
CHIK patients consulted an average of 2 days (range, 0 to 18
days) after the onset of symptoms, 232 (85.9%) from day 0 to 3, 30
(11.1%) from day 4 to 7, and 8 (3%) after day 7. The mean
duration of symptoms in the acute phase was 7 days (range, 1–24
days). Hospitalization was necessary for 42 patients (15.5%) with
more pronounced manifestations, and the mean length of stay was
2.6 days (range, 1 to 6 days).
At the time of the initial consultation, 230 (85%) patients
complained of fever, 246 (90.4%) had arthralgias, 197 (72.9%)
myalgias and 194 (71.8%) headaches (Figure 4). They all described
an abrupt onset of the illness.
Joint pain was mostly polyarticular, bilateral and symmetrical.
On average, 7 joints per patient were affected. Among the 246
patients with arthralgias, 100 (40.7%) had fewer than 5 affected
joints, and 146 (59.3%) had 5 or more affected joints. Arthralgias
occurred in the large joints (shoulders, elbows, wrists, knees,
ankles) in 242 (98.4%) patients, and in the lower limbs in 220
(89.4%) patients; the spine was affected in 146 (59.3%) patients.
Incapacitation was noted in 158 (64.2%) patients (Table 2), and
swelling of the elbows, wrists, knees or ankles was noted in one-
quarter of these patients (Figure 5A).
Myalgias mainly affected the forearms, arms, thighs and calves,
and sometimes became increasingly incapacitating. No cases of
myositis were seen. Headaches were beating or weighty, and were
located in the frontal, parietal, retro-orbital or, rarely, occipital
regions. Skin lesions were noted in 113 (41.8%) patients, in the
form of macular or maculopapular exanthema (Figure 5B),
morbiliform or bullous rash in a few children (Figure 5C), and
was accompanied by pruritus in one-quarter of cases. A more
aggressive form, with facial edema, was seen (Figure 5D). Peeling
of the affected skin occurred a few days after. Digestive symptoms,
consisting of abdominal pain, nausea, vomiting and diarrhea (87,
32%), were described, and mild bleeding of the nose and gums
reported (6, 2.2%) in patients with normal platelet counts. Seizures
occurred in 2 children (CSF was not sampled), who recovered
without sequelae.
No complications or deaths were reported.
Table 1. Distribution of suspected and confirmed cases
during the 2010 Chikungunya outbreak in south-east Gabon.
Suspected
Cases CHIK+ %
Haut-Ogooue Franceville 2063 933 45.2
Moanda 169 102 60.3
Mounana 112 45 40,1
Bongoville 36 9 25
Okondja 30 12 40
Ngouoni 14 10 71.4
Other 79 28 35.4
Ogooue Lolo Koulamoutou 195 56 28.7
Lastourville 9 1 11
Ndangui 24 12 50
Total 2731 1208 44.2
doi:10.1371/journal.pntd.0001517.t001
Figure 2. Distribution of Chikungunya confirmed cases according to the date of onset, in Franceville, 2010.
doi:10.1371/journal.pntd.0001517.g002
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The disease was classified in four forms accordingto the existence
of fever and/or arthralgias (plus any additional symptoms), namely
mixed (fever and arthralgias both present), pure febrile (fever
without arthralgias), pure arthralgic (arthralgias without fever), and
unusual (neither fever nor arthralgia).
Figure 3. Algorithm for cases selection.
doi:10.1371/journal.pntd.0001517.g003
Figure 4. Frequency of the main symptoms in patients with Chikungunya during the 2010 Franceville outbreak.
doi:10.1371/journal.pntd.0001517.g004
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arthralgic form in 34 (12.6%), the febrile form in 18 (6.7%), and
the unusual form in 6 (2.2%) (Figure 6A). Patients with the unusual
form mainly had digestive symptoms (Table 3).
The performance indicators of the ‘‘fever and arthralgia’’
combination were estimated in suspected patients (including PCR
negative patients), taking into account the true positive (TP), true
negative (TN), false positive (FP) and false negative (FN) results.
Figure 5. Photographs of clinical manifestations in CHIKV+ patients during the 2010 outbreak in Franceville, Gabon. A: Swelling of
the ankles and feet in a 43-year-old woman. B: Resolutive maculopapular rash of the arms in a 41-year-old man. C: Bullous vesicles on the thigh of a
3-year-old child. D: Rash with edema of the face in a 16-year-old girl.
doi:10.1371/journal.pntd.0001517.g005
Table 2. Location of arthralgias in CHIKV+ patients during the 2010 outbreak in Franceville, Gabon.
Total
n=246
Low Viral Load
n=58
High Viral Load
n=65 p value
n % n% n%
Articular groups Large joints 242 98.4 52 89.6 53 81.5 0.6
Small joints 94 38.2 14 24.1 19 29.2
Upper limbs Shoulders 71 29 15 25.8 9 13.8
Elbows 120 48.8 29 50 21 32.3 0.3
Wrists 141 57.3 26 44 31 47.7
Hands 81 32.9 12 20.7 15 23
Lower limbs Knees 170 69.1 36 62 35 53.8
Ankles 176 71.5 32 55.1 41 63 0.18
Feet 34 13.8 3 5.2 9 13.8
Spine 146 59.3 31 53.4 31 47.7
Intensity Severe 158 64.2 27 46.5 15 23
Moderate 81 33 22 37.9 18 27.7 0.02
Minimal 7 2.8 3 5.1 11 16.9
Low Viral Load: ,100 000 DNA cDNA genome equivalents/ml.
High Viral Load: $100 000 DNA cDNA genome equivalents/ml.
doi:10.1371/journal.pntd.0001517.t002
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(TN+FP), positive predictive value (PPV) as TP/(TP+FP) and
negative predictive value (NPV) as TN/(FN+TN). The ‘‘fever and
arthralgia’’ combination showed a sensitivity and specificity of
respectively 73.1% and 41% for PCR positivity, and PPV and
NPV of 78.5% and 34.4% (Table 4).
All four forms occurred throughout the outbreak, with a
majority of patients in the mixed form between week 18 to 23
(Figure 6B).
There was no significant difference in the mean duration of
symptoms (p=0.33) across the 4 clinical forms. Hospitalization
was necessary for 35 (16.5%) patients in the mixed form, 3 (8.8%)
patients in the arthralgic form, 4 (2.2%) patients in the febrile form
and none of the unusual form (p=0.33), and there was no
significant difference in the mean length of hospital stay (p=0.16).
Biological parameters
Hematological and biochemical parameters were available for
224 patients. Mean counts of leukocytes (524361676/mm
3, range
1900–11000/mm
3) and platelets (233 089681 750/mm
3, range
52000–455000/mm
3) did not differ from the controls. Neverthe-
less, anemia (mean hemoglobin 12.361.7 g/dl, range 8–17 g/dl),
and lymphocytopenia (mean lymphocyte count 22286216/mm
3,
range 184–7150/mm
3) were significantly frequent in CHIKV+
patients (respective p values 0.0009 and ,0.0001) than in the
controls. Liver enzymes (AST and ALT) and creatinine levels were
significantly higher (respective p values 0.03, 0.003 and ,0.0001)
in CHIKV+ patients than in controls (Table 5).
There was no significant difference in hemoglobin rate,
leukocyte, lymphocyte, or platelet count, or biochemical param-
eters across the four clinical forms.
Viral load
A total of 123 patients were selected for viral load (VL) assay.
The selection criteria included age, sex, site of consultation, area of
residence, week of disease onset, and clinical form. Their
characteristics were comparable to those of the initial sample.
The mean VL was 1.2610
7 (range, 1–4.4610
8). Fifty eight
patients (47.2%) had low VL (,100 000 DNA copies per mL,
Group 1), and 65 (52.8%) had high VL ($100 000 DNA copies,
Group 2). There was no difference in hemoglobin rate, leukocyte
or platelet count or biochemical data between the two groups.
However, lymphocytopenia was significantly more frequent
(p=0.01) in group 2 than in group 1. Moreover, there was no
Figure 6. Distribution of clinical forms. A: Distribution of the four clinical forms. B: Distribution of clinical forms according to the period of the
outbreak.
doi:10.1371/journal.pntd.0001517.g006
Table 3. Symptoms of patients with unusual forms.
Patients Age Sex Symptoms Biological disorders Viral load
1 42 Female Asthenia, myalgias, headaches, nausea Leukopenia ND
2 29 Female Asthenia None 10
1
3 45 Female Asthenia, nausea, vomiting, diarrhea None 1.92610
7
4 1 Male Vomiting, diarrhea None 6.63610
7
5 17 Female Rash None ND
6 37 Female Asthenia, headaches, nausea None 2.46610
5
ND: Not done; Viral load of 1 corresponds to a positive PCR signal detected outside the standard linearity. Viral loads are expressed in cDNA genome equivalents/ml.
doi:10.1371/journal.pntd.0001517.t003
Symptoms of Chikungunya in Gabon
www.plosntds.org 7 February 2012 | Volume 6 | Issue 2 | e1517difference in symptoms, affected joints (large vs small), their
location or intensity (Table 2).
There was no difference in VL according to the day of sampling
or symptom onset (day 0 to 3, day 4 to 7, and after day 7). VL did
not differ across the four clinical forms.
Outcome at month 3
Of the 270 CHIKV+ patients included in the study, 225
(83.3%) had completely recovered by day 30. The other 45
patients complained of persistence or relapse of fever (n=6),
arthralgias (n=36; incapacitating arthragias were still present in 5
patients), myalgias (n=11), headaches (n=20), pruritus (n=5) or
fatigue (n=10).
At day 90, 11 patients had persistent arthralgias. Among the 5
patients with incapacitating arthralgias, 4 recovered by day 90 and
one was lost to follow-up. Three patients had headaches.
Discussion
During a recent concomitant CHIKV/DENV outbreak which
occurred in south-east Gabon, we conducted a prospective study
in the most affected town, obtaining clinical and biological
descriptions of 270 laboratory-confirmed cases of CHIK. We
found variable clinical manifestations, including unusual forms.
This is the second large epidemic to be reported in Gabon, after
the concurrent CHIKV/DENV-2 intrusion in 2007, in which 2
provinces and 7 towns were affected. International shipping was
suspected of providing the portal of entry for both viruses [20].
Inside the country, the infection spread insidiously, along a north-
west/south-east axis via the railway and roads, leading to a new
outbreak in 2 provinces and 10 towns, 600 km distant and 3 years
later. Identified in Gabon just before 2007, in an area where Aedes
aegypti was previously predominant [36], Aedes albopictus was the
main vector of the first outbreak [20], and the second. Given the
rapid spread of this mosquito, even in temperate areas [18],
gradual invasion of the entire country by these viruses is
foreseeable.
This descriptive and prospective African study provides
exhaustive clinical and biological data than previous outbreaks
in the DRC, Republic of Congo, Cameroon and Gabon where
descriptions were succinct [7,19,20,37]. Available descriptions
have also been made in patients from la Reunion Island [25,26],
notably, in a prospective study [38].
A large number of patients were enrolled in this study. They
represented about one-third of all laboratory-confirmed cases, and
were distributed throughout the outbreak period, following the
global epidemic curve. This series is therefore largely representa-
tive of the epidemic, and is as large as two other studies which
included respectively 157 and 274 patients [25,38]. Other studies
included less than 100 patients [28,39,40]. However, some patients
with mild symptoms did not consult at the hospitals, and
constituted the unique bias of recruitment. So, the number of
enrolled patients is underestimated.
This study did not provided any information on asymptomatic
because patients’ recruitment occurred in the hospitals (individual
with symptoms only). In a recent study, asymptomatic CHIKV
infection was estimated at 28% [41]. With regard of the number of
CHIKV negative cases, the circulation of other arboviruses during
this epidemic cannot be ruled out. During the 2007 outbreak,
DENV-2 was detected [20] and a fatal case of West Nile virus
infection was diagnosed in Libreville [42]. Moreover, recent sero-
epidemiological studies have suggested the circulation of DENV,
WestNileandRiftValleyFever viruses inrural populations [43–45].
We observed marked clinical variability. As previously described,
fever and polyarthralgias were the most frequent manifestations,
affectingnearlyall thepatients[3,14,22,25,38,41].They werefound
in respectively 85% and 90% of our patients, and were both present
in three-quarters of cases. We found a weak association between the
‘‘fever and arthralgia’’ combination and PCR positivity, with a
sensitivity and specificity of73.1%and41%, whileinanotherrecent
study this combination had a diagnostic sensitivity of 84% and a
specificityof89%inanepidemicsetting[41].Differencesinthecase
definition and the assay could explain this discrepancy.
In its classical form, CHIK is a painful febrile illness char-
acterized by incapacitating arthralgias. Patients presenting with
a bent gait due joint pain, mainly affecting the wrists and ankles,
are easily recognizable. Incapacitating arthralgias are considered
pathognomonic for the disease. When the symptoms are less
severe, the clinical diagnosis becomes less clear-cut, and they may
Table 5. Comparison of laboratory findings in patients with acute Chikungunya and healthy controls.
Biological parameters CHIKV+, n=224 Controls, n=50 p value
Mean SD Mean SD
Hemoglobin 12.3 1.7 13.2 1.8 0.0009
WBC count, cell/mm
3 5243 1676 5242 1727 0.99
Lymphocytes count, cell/mm
3 2228 216 2039 205 ,0.0001
Platelet count, cell/mm
3 233089 81750 219000 66000 0.25
Aspartate aminotransferase level, UI/L 45 35 34 16 0.03
Alanine aminotransferase level, UI/L 33 17 25 19 0.003
Creatinine level, mmol/L 96 32 71 15 ,0.0001
doi:10.1371/journal.pntd.0001517.t005
Table 4. Performance indicators for the pair ‘‘fever and
arthralgia’’ in suspected patients.
Symptoms evaluated
Present Absent Total
Positive test 212 58 270
Negative test 78 41 119
Total 290 99 389
Sensitivity=73.1%; Specificity=41.4%; Positive Predictive Value=78.5%;
Negative Predictive Value=34.4%.
doi:10.1371/journal.pntd.0001517.t004
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fever. To date, only the classical DF has been reported in Africa.
To our knowledge, there is no comparative study of the two
diseases. Complications such as dengue hemorrhagic fever and
dengue with shock syndrome and persistent arthralgia following
CHIK constitute the noteworthy differences. In our field
experience, these diseases are clinically indistinguishable, and the
problem of differential diagnosis may be compounded during
concomitant CHIKV/DENV outbreaks in a malaria endemic
area.
Pure febrile and arthalgic forms were also seen, adding to the
clinical variability. The other symptoms were as frequent as in
previous studies [14,25,38,41]. Myalgias sometimes resulted in
incapacity. Rashes were easily diagnosed in our darker-skinned
population, and uncomplicated bullous lesions were also seen in
children. The mechanism by which bleeding occurs despite
normal platelet counts is unclear, but this classifies CHIK in the
viral hemorrhagic fever group, in this area where ebolavirus and
yellow fever virus also circulate.
We identified 2.2% of patients who had neither fever nor
arthralgias. These unusual forms were evoked in the Reunion
Island. This is their first description due to a strong clinical
presumption of physicians and a less sensitive and specific case
definition. Furthermore, no severe forms (requiring maintenance
of vital function) and deaths as described in the Reunion Island
[14,26] were noted in Gabon. In a context of frequent self-
medication, as in our study, many patients with unusual and non
severe forms did not consult a health service, and some of those
who did may have been misdiagnosed. So, the total number of
cases, in this epidemic, and the proportion of unusual forms, are
probably underestimated. Our findings imply that, during
epidemic periods, clinicians should not focus solely on fever and
arthralgias.
The four clinical forms were present throughout the outbreak
period, suggesting that pathogenicity did not vary markedly.
We also observed rare relapses or persistence of arthralgias, as
previously described [3,14,22]. The low rate of persisting
arthralgia in our sampling contrasts with previous studies [46–
48]. The little number of individuals followed up and the low
mean age (at 30 years) of our sampling could explain it. In
previous studies, the mean age of the population study was higher
(at 50 years) and the incidence of persistent arthralgia was higher
in older patients [46–48]. Immunonologic and genetic factors (anti
CCP antibodies, antinuclear antibodies and HLA DR alleles) are
associated with rheumatoid arthritis following Chikungunya fever
[49]. Their absence in our patients could also explain low rate of
persistent arthralgia.
In CHIKV infections, biological abnormalities are varied,
transient and nonspecific, as in many other viral diseases [25,38].
In our study, biological data from CHIKV+ patients were
compared with those of healthy volunteers than CHIKV-, in
order to avoid a bias in results interpretation. CHIKV- patients
were considered as having another disease. Varied biological
abnormalities were found. Anemia may have been due to parasitic
coinfection (ankylostomiasis, ascariasis). Lymphocytopenia corre-
lated with viremia, as recently described [38], and is probably due
to excessive apoptosis with peripheral lymphocyte destruction.
The increase in liver enzyme and creatinine levels may have been
due to drug toxicity (particularly when ibuprofen and paracetamol
are associated), muscle damage or even rhabdomyolysis. Finally,
the disease severity did not correlate with VL in our study,
contrary to a recent study in which the severity criteria were
different [50]. Together, these findings imply that symptoms are
not directly related to the virus but rather to the immune reaction.
Theoretically, PCR is the preferred method for detecting and
quantifying CHIKV viral RNA, mainly during the first week after
infection [4,5]. The detection of the virus later than 7 days after
symptom onset in 3% of our patients is surprising. It is conceivable
that their initial symptoms were due to another disease such as
malaria or dengue, before they contracted CHIKV.
The genotype of CHIV implicated in Gabonese and Camer-
oonian outbreaks belongs to the ESCA phylogroup and harbor the
A226V mutation [20]. This mutation has also been found in
samples from La Reunion Island which the genotype belongs to
the Asian phylogroup. This mutation improves replication and
transmission efficiency in Aedes albopictus mosquitoes [6]. To date,
no genotype and no mutation have been found associated with
specific clinical forms.
Finally, our study showed that this outbreak, as the first one,
occurred during the rainy season and Aedes albopictus was the main
vector, with an extension in other parts of the country. Globally,
the clinical picture did not differ from Asian, European and Indian
Ocean Islands studies. The acute phase and outcome seemed
similar, as biological abnormalities and treatment efficacy. In the
other hand, there were some noteworthy distinctive features: the
mean duration of symptoms in the acute phase is long (7 days
reaching to 24 days), relapses and persistent arthralgia were rare,
there were no severe forms or deaths, and unusual forms were well
described.
Epidemiological surveillance must continue in order to detect
any change in the pathogenicity of CHIKV.
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